Benefit Chinese diabetics! Lilly and Nccd reach cooperation

Source: Wuxi apptec April 26, 2017, Eli Lilly and China National Center for cardiovascular disease (Nccd) jointly announced that they would work together to promote the research on type 2 diabetes and related complications including cardiovascular disease (CVD), and strive to improve medical care for patients Diabetes is a chronic disease caused by the body's inability to produce or use insulin normally At present, there are 425 million adults with diabetes in the world, 90% of them are type 2 diabetes It is predicted that the number of diabetics in the world will reach 629 million by 2025 Diabetes not only causes the blood sugar to rise, but also can lead to a variety of complications CVD is an important complication and the primary factor leading to the death of diabetic patients CVD is responsible for about 50% of type 2 diabetes deaths worldwide In China, the proportion of people with diabetes increased from 1% in 1980 to 11% in 2017, and more than one third of the population is in pre diabetes At present, less than one third of diabetic patients in China receive treatment In response to this national epidemic, Nccd and Lilly will work together to promote a scientific understanding of type 2 diabetes and its complications in four areas: assessing the health and economic consequences of diabetes in China Develop a simple calculation method to assess CVD risk, so as to improve the screening and diabetes care process at the level of primary care doctors Through the analysis of patients' samples, we found new biomarkers of diabetes progression, diabetic nephropathy and CVD Develop and disseminate medical education materials for medical staff in China to treat diabetes related CVD Lilly's cooperation with Nccd will take advantage of data obtained from the China patient centered assessment of cardiac events million people project, the first large-scale national cardiovascular disease screening and epidemiological research project in China The China Peace million population project will provide data on more than one million patients with type 2 diabetes or high-risk groups of CVD ▲ Dr Jiang Lixin, vice president of Fuwai Hospital and assistant director of Nccd (photo source: Official Website of Fuwai Hospital, Chinese Academy of Medical Sciences), "with the rapid increase of the number of diabetic patients in China, we must solve the impact of this disease on human and economy," said Vice President of Fuwai Hospital and Nccd "By improving our understanding of diabetes and cardiovascular disease, we may significantly improve our medical care for the Chinese people," said Dr Jiang Lixin, assistant director "We are very grateful for Nccd's willingness to cooperate with us to promote the understanding of these complex diseases in the above direction," said Dr Robert Heine, distinguished Lily scholar "We hope that through this cooperation we can obtain knowledge and tools that can benefit the patients with type 2 diabetes in China and the world."